Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 786 across all filing types
Latest filing 2016-11-08 Regulatory Filings
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2016. It reports the issuance of a press release for financial and operational results for the third quarter ended September 30, 2016, and also mentions an updated corporate presentation attached as exhibits. The document itself does not contain the full financial statements or detailed financial data but rather announces the release of these materials. The length is only 2599 characters, indicating it is a brief announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of reports and presentations, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such SEC Form 8-K filings that announce but do not contain full reports.
2016-11-08 English
10-Q
Interim / Quarterly Report 9M 2016
2016-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce specific events. The content includes a press release about the issuance of a US patent and does not contain financial statements or detailed financial data. The document length is 2252 characters, which is relatively short and primarily serves as an announcement rather than a full report. There is no indication of quarterly or annual financial results, management discussion, or other detailed report content. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-11-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 17, 2016, by Lipocine Inc. It announces the completion of a post action meeting with the FDA regarding a new drug application. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 2433 characters, which is relatively short and consistent with an announcement rather than a full report. The content is primarily a regulatory disclosure about a specific event, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-10-17 English
8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 7, 2016, by Lipocine Inc. It announces the dismissal of a patent infringement lawsuit and includes a press release as an exhibit. The content is a regulatory announcement about a legal proceeding outcome, not a full audit report or annual/quarterly financial report. The document is short (2314 characters) and primarily serves as a notification of a legal event. Therefore, it fits best under Legal Proceedings Report (LTR).
2016-10-08 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 27, 2016, by Lipocine Inc. It announces that the company will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference and that presentation materials are attached as an exhibit. The text does not contain actual financial statements or detailed financial analysis but rather serves as a notification of an investor presentation event and the availability of presentation materials. The document length is short (2317 characters), and it primarily serves as an announcement rather than the presentation itself. According to the classification rules, such documents are best classified as Investor Presentation (IP) filings because they focus on financials, strategy, and market position presented to investors, even if the actual presentation is attached as an exhibit.
2016-09-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.